This HTML5 document contains 156 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n11http://dx.doi.org/10.1016/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q43784378
rdf:type
wikibase:Item
schema:description
artikel ilmiah مقالة علمية نشرت في 11 يونيو 2013 2013年學術文章 บทความทางวิทยาศาสตร์ artigo científico wetenschappelijk artikel artículo científico publicado en 2013 scientific article published on 11 June 2013 articolo scientifico scienca artikolo 2013년 논문 teaduslik artikkel 2013年學術文章 2013年学术文章 სამეცნიერო სტატია bài báo khoa học мақолаи илмӣ מאמר מדעי tudományos cikk 2013年学术文章 artigo científico vedecký článok wissenschaftlicher Artikel 2013年學術文章 vitenskapelig artikkel vetenskaplig artikel article scientific επιστημονικό άρθρο научная статья scientific article published on 11 June 2013 artikulong pang-agham ১১ জুন ২০১৩-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ videnskabelig artikel 2013年の論文 наукова стаття, опублікована в червні 2013 vědecký článek 2013年学术文章 2013年學術文章 artículu científicu espublizáu en 2013 naučni članak article científic 2013 nî lūn-bûn vitskapeleg artikkel artigo científico научни чланак articol științific bilimsel makale tieteellinen artikkeli artykuł naukowy 2013年学术文章 2013年学术文章 2013年學術文章 научна статия scientific article published on 11 June 2013 научни чланак artikull shkencor article scientifique 2013 թվականի հունիսի 11-ին հրատարակված գիտական հոդված 2013年学术文章
p:P577
wds:Q43784378-F1F64B43-0A09-4FFD-BDAA-830E87E9DA65
wdt:P577
2013-06-11T00:00:00Z
p:P2860
wds:Q43784378-088C7E72-122E-4D8F-ACB9-4E15B86F1594 wds:Q43784378-0BB831BF-FBCE-4DCA-90A0-2982A0DF42EE wds:Q43784378-220A41B7-D8EB-42F6-AE9F-2156F125F45A wds:Q43784378-2A30E224-A523-43AB-9FCC-C583D7E90FE1 wds:Q43784378-AADD213C-2C4F-4DD7-BFF6-9883B0936977 wds:Q43784378-CDF0B6A3-35F1-4A38-A316-6FCC6299205A wds:Q43784378-CF876E46-752D-4D5D-89F8-757FE42ED106 wds:Q43784378-D3A678F2-8373-4A8D-B77B-572573B7B4D9 wds:Q43784378-D92742DE-9A5F-44C6-9D13-04D5BCDDCD8C wds:Q43784378-3BAC7492-F072-424F-B81E-581C6C4D855A wds:Q43784378-4EBEA6B1-9F8B-4762-820C-CCEDCAFBFDB9
wdt:P2860
wd:Q35710898 wd:Q33964848 wd:Q34496969 wd:Q27824847 wd:Q53243856 wd:Q33993977 wd:Q29616112 wd:Q35609706 wd:Q83203060 wd:Q43241014 wd:Q53158182
p:P2093
wds:Q43784378-81116ABA-F56A-4762-8FA1-26A30D944EE8 wds:Q43784378-7B59B54B-3A73-4762-951F-42BA72326AAE wds:Q43784378-5BB69120-1A0B-4F53-BF72-653E1B2ACCDE wds:Q43784378-654B2B70-5F47-4C32-8F92-C6A3B27D18E0 wds:Q43784378-B5AD0EF8-60D4-46FC-8BD1-3C518D956C03 wds:Q43784378-C1FCA285-BAA0-4884-B957-1B0191EB1332 wds:Q43784378-B432A430-CED6-4944-B33F-D4D9C4BCF9F4 wds:Q43784378-FD2BBDD8-5409-4D9C-9F8B-C1DA6D45C958 wds:Q43784378-F774716E-5B9E-4FB3-A5F4-5C36DFC38660 wds:Q43784378-EC1E6FBF-466E-4CBE-ABD9-00ECC4D7C0BF wds:Q43784378-0F8546BB-A8A5-453D-ADFD-1FCB28726415 wds:Q43784378-06D58C49-1641-4BFB-8E25-FCE1C4BF09BC wds:Q43784378-046E5A6B-77F0-44F1-9E83-9B22BD9BBAAE wds:Q43784378-336511AF-ED39-4333-9078-60E3815F3DE9 wds:Q43784378-26108484-5BDA-4207-A7AA-7528FBC9E25F wds:Q43784378-29EF68F9-6C42-4341-B54B-CBD0439CECD7 wds:Q43784378-4CDFCD17-2F42-4639-AF6D-3C6D3364E197 wds:Q43784378-4350006C-6DA6-44DB-808D-C243B15D95E8
wdt:P2093
Marc Debled Gilles Romieu PHARE trial investigators Iris Pauporté Andrew Kramar David Khayat Alain Lortholary Marc Espié Maria Rios Laurent Cany Sophie Abadie-Lacourtoisie Jean-Philippe Jacquin Jean-Yves Pierga Daniel Serin Pierre Fumoleau Christelle Jouannaud Stéphanie Catala Pierre Kerbrat
rdfs:label
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer
skos:prefLabel
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer
schema:name
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer
p:P50
wds:Q43784378-24F859D9-3F00-4B95-8430-9099FCE1A157 wds:Q43784378-53C73C97-9759-41FE-AA62-773D8C39D07C wds:Q43784378-439895B1-F5E6-4180-95E4-2DC32D22FB70 wds:Q43784378-D4D270B0-DE6C-4E73-99C8-215E22867E40
wdt:P50
wd:Q89504757 wd:Q51368266 wd:Q66829173 wd:Q43142972
p:P1476
wds:Q43784378-6E1731F6-6FB7-443B-8369-ECC1474C6828
wdt:P1476
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
p:P304
wds:Q43784378-AAFB4986-D6D2-406E-B2F9-A7E42021090F
wdt:P304
741-748
p:P31
wds:Q43784378-98C57304-3C34-4A46-9AA3-5658F497C6F1
wdt:P31
wd:Q13442814
p:P921
wds:Q43784378-203543B5-5AFA-4FAC-A235-D2419A2E3525 wds:Q43784378-ACFDB377-38A6-4918-AFA8-08598D458032
wdt:P921
wd:Q412616 wd:Q42824827
p:P698
wds:Q43784378-AAD1AC4A-F58E-4C36-8F86-E2F83790E70C
wdtn:P698
n12:23764181
wdt:P698
23764181
p:P1433
wds:Q43784378-48A79A87-E496-4A4A-BC7B-147FE3647931
wdt:P1433
wd:Q13747613
p:P433
wds:Q43784378-44E4942E-5B3B-42F3-8AC7-BC07B088B833
p:P478
wds:Q43784378-127CFBD7-6E64-4E50-9E2C-FCC235F4ECB6
wdt:P433
8
wdt:P478
14
p:P356
wds:Q43784378-8C6A7423-61D8-496A-85BE-6939AA86F378
wdtn:P356
n11:S1470-2045(13)70225-0
wdt:P356
10.1016/S1470-2045(13)70225-0